Journal of Dermatology for NPs & PAs

28/06/2024

Straight out of Maui Derm: Dermatomyositis Treatment Update

Watch here: https://jdnppa.com/?vimeography_gallery=14&vimeography_video=963700178

27/06/2024

The U.S. FDA has approved sofpironium topical gel, 12.45% (Sofdra, Botanix) for primary axillary hyperhidrosis in adults and children aged nine and older.

The U.S. Food and Drug Administration has approved sofpironium topical gel, 12.45% (Sofdra, Botanix) for primary axillary hyperhidrosis in adults and children aged nine and older. The FDA approval was supported by results from the two pivotal Phase 3 ‘CARDIGAN’ studies which evaluated the effica...

26/06/2024

Brett King, MD, PhD, an Associate Professor of Dermatology at Yale University School of Medicine, shares highlights from the inaugural 2024 Revolutionizing Areata, , and (RAVE) conference in Chicago, including important information about new and emerging treatment options.

Brett King, MD, PhD, an Associate Professor of Dermatology at Yale University School of Medicine in New Haven, CT, shares highlights from the inaugural 2024 Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) conference in Chicago, including important information about new and emerging trea...

17/06/2024

Welcome to JDNPPA, Natalie George, PA-C!

14/06/2024

The U.S. FDA approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin (Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm2.

The U.S. Food and Drug Administration (FDA) approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin (Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm2. Klisyri, a microtubule inhibitor ointment, is now approve...

13/06/2024

JUST IN: The US FDA has given its nod to tralokinumab-ldrm (Adbry, LEO Pharma) 300mg single-dose autoinjector for adults with moderate to severe (AD).

The U.S. Food and Drug Administration (FDA) has given its nod to tralokinumab-ldrm (Adbry, Leo Pharma) 300mg single-dose autoinjector for adults with moderate to severe atopic dermatitis (AD). Tralokinumab-ldrmis is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the...

12/06/2024

Welcome to the team, Melissa Baughcum, NP!

11/06/2024

Fresh issue, hot off the press is available here!

Immunodermatology Today Clinical updates on the treatment of atopic dermatitis, systemic lupus erythematosus, dermatomyositis, psoriasis, and other immune-mediated skin diseases. Fresh-From-the-Podium Dermatology Meeting Coverage Dialogues in Dermpath Unpacking New AD Guidelines By NPs and PAs For N...

09/06/2024

The International Psoriasis Council (IPC) recently released an international consensus statement on the definition and diagnostic criteria for generalized pustular psoriasis (GPP).

The International Psoriasis Council (IPC) recently released an international consensus statement on the definition and diagnostic criteria for generalized pustular psoriasis (GPP). The consensus was developed using the modified Delphi method and is published in JAMA Dermatology. In it, GPP is define...

07/06/2024

Welcome to JDNPPA, Victoria Garcia-Albea, NP!

06/06/2024

Upadacitinib (Rinvoq, AbbVie) is now available in the U.S. as a tablet or an oral solution for the treatment of pediatric patients aged 2 and older with active (PsA) as well as polyarticular juvenile idiopathic arthritis (pJIA), provided patients have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, AbbVie reports.

Upadacitinib (Rinvoq, AbbVie) is now available in the U.S. as a tablet or an oral solution for the treatment of pediatric patients aged 2 and older with active psoriatic arthritis (PsA) as well as polyarticular juvenile idiopathic arthritis (pJIA), provided patients have had an inadequate response o...

05/06/2024

The Dermatology Education Foundation(DEF) and ReachRx, are collaborating to increase awareness of and access to each organization’s products and services.

The collaboration launches June 3, and DEF subscribers will gain free access to ReachRx Pro for up to one year. To register, DEF subscribers can follow this dedicated link.

The Dermatology Education Foundation (DEF) and ReachRx, are collaborating to increase awareness of and access to each organization’s products and services. The collaboration launches June 3, and DEF subscribers will gain free access to ReachRx Pro for up to one year. To register, DEF subscribers ...

02/06/2024

Welcome to the Dream Team, Patricia Delgado, NP!

31/05/2024

Low-dose isotretinoin may help reduce symptoms, according to a systematic review published in JAAD International.

Researchers led by Adam Friedman, MD, Professor and Chair of Dermatology at The George Washington University School of Medicine and Health Sciences, and Sapana Desai, MD, MPH, dermatology research fellow at GW, evaluated the available data to highlight the benefits of using isotretinoin for rosacea.

Low-dose isotretinoin may help reduce rosacea symptoms, according to a systematic review published in JAAD International. Researchers led by Adam Friedman, MD, Professor and Chair of Dermatology at the George Washington (GW) University School of Medicine and Health Sciences in Washington, DC, and Sa...

29/05/2024

TDD Editorial Advisory Board Member Raj Chovatiya, MD, PhD, the Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, updates viewers on the true role of Malassezia yeast in the pathophysiology of seborrheic dermatitis and explains how this new understanding....

28/05/2024

Giving a big Texas welcome to board member, Matt Bruno, PA-C!

26/05/2024

The U.S FDA gave its nod to isotretinoin (Accutane, Hoffmann-La Roche) as an oral prescription medication for treating severe acne in 1982. Since then, acne specialists have learned a lot about how to best use this drug.

Shanna Miranti, MPAS, PA-C, a board-certified physician assistant at Riverchase Dermatology in Naples, FL, updates viewers on new monitoring protocols for patients taking , the drug’s side effect profile and potential for teratogenicity, and the isotretinoin brands that are currently available for patients. https://jdnppa.com/hack-your-accutane-prescribing-tip-no-1-know-your-history/

23/05/2024

Genetics play a larger role in risk than previously recognized, new research suggests.

Genetics play a larger role in melanoma risk than previously recognized, new research suggests. Physicians rarely order genetic screens to assess risk factors for patients with a family history of melanoma because, according to the previous, limited studies, only 2-2.5% of all cases are genetic. For...

22/05/2024

Join us in welcoming Matt Brunner, PA-C to the JDNPPA Board!

19/05/2024

The Federal Trade Commission has banned non-compete clauses for employers and workers, and in many cases, the ban applies retroactively.

Here’s what employers, dermatologists, dermatology nurse practitioners (NPs) and physician’s assistants (PAs) need to know:

The Federal Trade Commission (FTC) has banned non-compete clauses for employers and workers, and in many cases, the ban applies retroactively. Here’s what employers, dermatologists, dermatology nurse practitioners (NPs) and physician’s assistants (PAs) need to know: 1. The new ban is slated to t...

18/05/2024

A microneedle patch that delivers immune-regulating molecules may teach T cells not to attack hair follicles, helping regrow hair in areata, according to research in mice from Massachusetts Institute of Technology (MIT), Brigham and Women's Hospital, and Harvard Medical School.

The team developed a microneedle patch that can be painlessly applied to the scalp and releases drugs that help to rebalance the immune response at the site, halting the autoimmune attack.

A microneedle patch that delivers immune-regulating molecules may teach T cells not to attack hair follicles, helping regrow hair in alopecia areata, according to research in mice from MIT, Brigham and Women’s Hospital, and Harvard Medical School. The team developed a microneedle patch that can be...

17/05/2024

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial.

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. Week 208 responses for Psoriasi...

16/05/2024

Hi, we're new here! Allow us to introduce our editorial board.
Welcome, Tracee Blackburn, PA-C!

15/05/2024

Shanna Miranti, MPAS, PA-C, a board-certified physician assistant at Riverchase Dermatology in Naples, FL, updates viewers on new monitoring protocols for patients taking isotretinoin, the drugs’ side effect profile and potential for teratogenicity, and the isotretinoin brands that are currently available for acne patients with . https://jdnppa.com/hack-your-accutane-prescribing-tip-no-1-know-your-history/